Clinical Trial Update: Effect of a Proposed Cav1.3 Inhibitor in Primary Aldosteronism [NA]

View source ↗

Summary

This clinical trial update reports that the study evaluating a proposed Cav1.3 inhibitor for primary aldosteronism has completed. The sponsor is Queen Mary Univ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aldosteronism
• Hypertension

Drugs mentioned

• Cav1.3 inhibitor (proposed)

Snippet

Sponsor: Queen Mary University of London | Conditions: Primary Aldosteronism, Endocrine Hypertension | NA | Status: COMPLETED